Premium
Individualizing treatment for patients with nasopharyngeal cancer
Author(s) -
Hara Wendy,
Le QuynhThu
Publication year - 2015
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.29418
Subject(s) - medicine , biomarker , oncology , chemoradiotherapy , nasopharyngeal cancer , genotype , cancer , prospective cohort study , single nucleotide polymorphism , ercc1 , radiation therapy , nasopharyngeal carcinoma , dna , genetics , gene , dna repair , biology , nucleotide excision repair
In this issue, Dr. Hui and colleagues report the largest multi‐institutional, prospective trial to date validating circulating Epstein‐Barr virus DNA as a prognostic biomarker for patients with nasopharyngeal cancer after chemoradiotherapy. The ERCC1 C118T single nucleotide polymorphism genotype may also be a potential second biomarker for future investigation.